In the press

Matthew Read comments on the IEM tender result in Investment Week

Biotech trusts top performance charts in February

Matthew Read comments on the IEM tender in Linus Uhlig’s article:

“Viewed one way, this whole saga looks like a futile exercise. Saba forced through its agenda by overriding the wishes of independent shareholders in what appeared to be a scramble to corral assets under management, only to throw in the towel at the final hurdle by tendering the bulk – if not all – of its own holding.”

Read the article here: